OpenLegislation

Division 4.1 Format and PresentationF1

United Kingdom

Original text. Later amendments are not shown.

The general outline of Module 4 is as follows:

  • Table of contents

  • Study reports

    • Pharmacology

      • Primary Pharmaco-dynamics

      • Secondary Pharmaco-dynamics

      • Safety Pharmacology

      • Pharmaco-dynamic Interactions

    • Pharmaco-kinetics

      • Analytical Methods and Validation Reports

      • Absorption

      • Distribution

      • Metabolism

      • Excretion

      • Pharmaco-kinetic Interactions (non-clinical)

      • Other Pharmaco-kinetic Studies

    • Toxicology

      • Single-Dose Toxicity

      • Repeat-Dose Toxicity

      • Genotoxicity

        • In vitro

        • In vivo (including supportive toxico-kinetics evaluations)

      • Carcinogenicity

        • Long-term studies

        • Short- or medium-term studies

        • Other studies

      • Reproductive and Developmental Toxicity

        • Fertility and early embryonic development

        • Embryo-fetal development

        • Prenatal and postnatal development

        • Studies in which the offspring (juvenile animals) are dosed and/or further evaluated

      • Local Tolerance

    • Other Toxicity Studies

      • Antigenicity

      • Immuno-toxicity

      • Mechanistic studies

      • Dependence

      • Metabolites

      • Impurities

      • Other

  • Literature references

Annotations

Textual amendments

F1

Substituted by Commission directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance).